Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine

Vaccine

Volumn 28, Issue 2, 2009, Pages 403-414

  Hunter, Zoe ^a   Smyth, Hugh D ^b   Durfee, Paul ^a   Chackerian, Bryce ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Aerosol; CCR5; HIV vaccine; Mucosal immunity; VLP

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

AEROSOL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; DRUG RECEPTOR BINDING; FECES; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LUNG LAVAGE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RAT; SIMIAN IMMUNODEFICIENCY VIRUS; UTERUS; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; FEMALE; FLOW CYTOMETRY; HIV; IMMUNITY, MUCOSAL; INJECTIONS, INTRAMUSCULAR; MICE; MODELS, BIOLOGICAL; RATS; RECEPTORS, CCR5; VACCINATION; VACCINES, VIROSOME;

EID: 70649097215     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.035     Document Type: Article

References (56)

1. Spohn G., and Bachmann M.F. Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines 7 February (1) (2008) 43-54
2. Chackerian B., Durfee M.R., and Schiller J.T. Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 180 May (9) (2008) 5816-5825
3. Chackerian B., Lowy D.R., and Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108 August (3) (2001) 415-423
4. Chackerian B., Lenz P., Lowy D.R., and Schiller J.T. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169 11 (2002) 6120-6126
5. Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25 January (1) (2007) 63-72
6. Chackerian B., Rangel M., Hunter Z., and Peabody D.S. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 24 September (37-39) (2006) 6321-6331
7. Li Q., Cao C., Chackerian B., Schiller J., Gordon M., Ugen K.E., et al. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci 5 June (1) (2004) 21
8. Zamora E., Handisurya A., Shafti-Keramat S., Borchelt D., Rudow G., Conant K., et al. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol 177 August (4) (2006) 2662-2670
9. Spohn G., Guler R., Johansen P., Keller I., Jacobs M., Beck M., et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178 June (11) (2007) 7450-7457
10. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 5270 (1996) 1955-1958
11. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 7 (1996) 1149-1158
12. Deng H.K., Unutmaz D., KewalRamani V.N., and Littman D.R. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388 July (6639) (1997) 296-300
13. Li S., Juarez J., Alali M., Dwyer D., Collman R., Cunningham A., et al. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol 73 December (12) (1999) 9741-9755
14. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
15. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
16. Winkler C., Modi W., Smith M.W., Nelson G.W., Wu X., Carrington M., et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 279 (1998) 389-393
17. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11 November (11) (2005) 1170-1172
18. Hunt J.S., and Romanelli F. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 29 March (3) (2009) 295-304
19. Yost R., Pasquale T.R., and Sahloff E.G. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm 66 April (8) (2009) 715-726
20. Barassi C., Soprana E., Pastori C., Longhi R., Buratti E., Lillo F., et al. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol 79 June (11) (2005) 6848-6858
21. Bogers W.M., Bergmeier L.A., Oostermeijer H., ten Haaft P., Wang Y., Kelly C.G., et al. CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection. Vaccine 22 August (23-24) (2004) 2974-2984
22. Bogers W.M., Bergmeier L.A., Ma J., Oostermeijer H., Wang Y., Kelly C.G., et al. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. Aids 18 January (1) (2004) 25-36
23. Zuber B., Hinkula J., Vodros D., Lundholm P., Nilsson C., Morner A., et al. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Virology 278 December (2) (2000) 400-411
24. Misumi S., Nakayama D., Kusaba M., Iiboshi T., Mukai R., Tachibana K., et al. Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge. J Immunol 176 January (1) (2006) 463-471
25. Chain B.M., Noursadeghi M., Gardener M., Tsang J., and Wright E. HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor. Vaccine 26 October (45) (2008) 5752-5759
26. Chackerian B., Lowy D.R., and Schiller J.T. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci USA 96 (1999) 2373-2378
27. Chackerian B., Briglio L., Albert P.S., Lowy D.R., and Schiller J.T. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 78 April (8) (2004) 4037-4047
28. Veazey R., and Lackner A. The mucosal immune system and HIV-1 infection. AIDS Rev 5 October-December (4) (2003) 245-252
29. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 April (Suppl. 4) (2005) S45-S53
30. Levine M.M. Can needle-free administration of vaccines become the norm in global immunization?. Nat Med 9 January (1) (2003) 99-103
31. Roy C.J., Hale M., Hartings J.M., Pitt L., and Duniho S. Impact of inhalation exposure modality and particle size on the respiratory deposition of ricin in BALB/c mice. Inhal Toxicol 15 May (6) (2003) 619-638
32. Swanson K.A., Zheng Y., Heidler K.M., Mizobuchi T., and Wilkes D.S. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol 30 March (3) (2004) 311-318
33. Kimata J.T., Gosink J.J., KewalRamani V.N., Rudensey L.M., Littman D.R., and Overbaugh J. Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne. J Virol 73 February (2) (1999) 1655-1660
34. Edinger A.L., Amedee A., Miller K., Doranz B.J., Endres M., Sharron M., et al. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci USA 94 April (8) (1997) 4005-4010
35. Wu L., LaRosa G., Kassam N., Gordon C.J., Heath H., Ruffing N., et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 186 8 (1997) 1373-1381
36. Farzan M., Mirzabekov T., Kolchinsky P., Wyatt R., Cayabyab M., Gerard N.P., et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96 March (5) (1999) 667-676
37. Misumi S., Nakajima R., Takamune N., and Shoji S. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine. J Virol 75 December (23) (2001) 11614-11620
38. Peabody D.S., Manifold-Wheeler B., Medford A., Jordan S.K., do Carmo Caldeira J., and Chackerian B. Immunogenic display of diverse peptides on Virus-like Particles of RNA phage MS2. J Mol Biol 380 June (27) (2008) 252-263
39. Parent R.A. Comparative biology of the normal lung (1992), CRC Press, Boca Raton
40. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6 June (3) (2007) 381-390
41. Jennings G.T., and Bachmann M.F. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 49 (2009) 303-326
42. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 165 November (9) (2000) 5170-5176
43. Mazzoli S., Trabattoni D., Lo Caputo S., Piconi S., Ble C., Meacci F., et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3 November (11) (1997) 1250-1257
44. Hladik F., Sakchalathorn P., Ballweber L., Lentz G., Fialkow M., Eschenbach D., et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26 February (2) (2007) 257-270
45. Lopalco L., Barassi C., Pastori C., Longhi R., Burastero S.E., Tambussi G., et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol 164 6 (2000) 3426-3433
46. Balmelli C., Demotz S., Acha-Orbea H., De Grandi P., and Nardelli-Haefliger D. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. J Virol 76 December (24) (2002 Dec) 12596-12602
47. Bessa J., Schmitz N., Hinton H.J., Schwarz K., Jegerlehner A., and Bachmann M.F. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 38 January (1) (2008) 114-126
48. Balmelli C., Roden R., Potts A., Schiller J., De Grandi P., and Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72 October (10) (1998) 8220-8229
49. Revaz V., Zurbriggen R., Moser C., Schiller J.T., Ponci F., Bobst M., et al. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res 76 October (1) (2007) 75-85
50. Johansson E.L., Wassen L., Holmgren J., Jertborn M., and Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 69 December (12) (2001) 7481-7486
51. Nardelli-Haefliger D., Lurati F., Wirthner D., Spertini F., Schiller J.T., Lowy D.R., et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23 May (28) (2005) 3634-3641
52. Brandtzaeg P., and Johansen F.E. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 206 August (2005) 32-63
53. Butcher E.C., Williams M., Youngman K., Rott L., and Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol 72 (1999) 209-253
54. Bowman E.P., Kuklin N.A., Youngman K.R., Lazarus N.H., Kunkel E.J., Pan J., et al. The intestinal chemokine thymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells. J Exp Med 195 January (2) (2002) 269-275
55. Freytag L.C., and Clements J.D. Mucosal adjuvants. Vaccine 23 March (15) (2005) 1804-1813
56. Sanchez J., and Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci 65 May (9) (2008) 1347-1360